Intellia Therapeutics (NTLA) SEC Filings: History & Chart

Intellia Therapeutics, Inc.(NTLA)

Biotechnology · Cambridge, MA

$12.26+0.14 (+1.16%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Cambridge, MA

377 employees

www.intelliatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Leonard

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 8, 2026	Sep 8, 2026	View filing
8-K	Sep 4, 2026	Sep 4, 2026	View filing
4	Aug 24, 2026	Aug 24, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
4	Jul 24, 2026	Jul 24, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
8-K	Jun 10, 2026	Jun 10, 2026	View filing
10-Q	May 11, 2026	May 11, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
8-K	Apr 30, 2026	Apr 30, 2026	View filing
ARS	Apr 30, 2026	Apr 30, 2026	View filing
DEFA14A	Apr 30, 2026	Apr 30, 2026	View filing
DEF 14A	Apr 30, 2026	Apr 30, 2026	View filing
SC 13G	Apr 30, 2026	Apr 30, 2026	View filing
424B5	Apr 29, 2026	Apr 29, 2026	View filing
SC 13G	Apr 29, 2026	Apr 29, 2026	View filing
424B5	Apr 27, 2026	Apr 27, 2026	View filing
8-K	Apr 27, 2026	Apr 27, 2026	View filing
8-K	Apr 10, 2026	Apr 10, 2026	View filing

SEC Filings

Recent Filings